Abstract
Restless legs syndrome (RLS) is a common disorder that can have a considerable impact on a patient's functioning and quality of life. The pharmacologic armamentarium for RLS contains dopamine agonists, a-2d ligands, and opioids, among other agents. Each of these types of drugs has strengths and limitations, and treatment selection should be based on the frequency of RLS symptoms and any accompanying pain. Dopaminergic augmentation, which exacerbates RLS symptoms, is the most common and challenging side effect of long-term RLS treatment with dopamine agonists and requires special clinical consideration. Iron status is also important to the effective management of RLS.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
-
Video-Audio Media
MeSH terms
-
Amines / therapeutic use
-
Analgesics, Opioid / adverse effects
-
Analgesics, Opioid / therapeutic use
-
Carbamates / therapeutic use
-
Cyclohexanecarboxylic Acids / therapeutic use
-
Dopamine Agonists / adverse effects
-
Dopamine Agonists / therapeutic use
-
Gabapentin
-
Humans
-
Iron Compounds / therapeutic use
-
Pregabalin
-
Restless Legs Syndrome / drug therapy*
-
gamma-Aminobutyric Acid / analogs & derivatives
-
gamma-Aminobutyric Acid / therapeutic use
Substances
-
1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid
-
Amines
-
Analgesics, Opioid
-
Carbamates
-
Cyclohexanecarboxylic Acids
-
Dopamine Agonists
-
Iron Compounds
-
Pregabalin
-
gamma-Aminobutyric Acid
-
Gabapentin